Azacitidine Production Cost Reports

The report provides a detailed analysis essential for establishing an Azacitidine production plant. It encompasses all critical aspects necessary for Azacitidine production, including the cost of Azacitidine production, Azacitidine plant cost, Azacitidine production costs, and the overall Azacitidine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Azacitidine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Azacitidine is a medication primarily used in the treatment of certain types of cancer, particularly myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). It is mainly utilised for the treatment of myelodysplastic syndrome, myeloid leukaemia, and juvenile myelomonocytic leukaemia. It works by inhibiting the growth of abnormal cells in the bone marrow, which helps to promote the production of healthy blood cells. It is often used as part of a combination therapy to increase its effectiveness. Moreover, Azacitidine is also used in the treatment of other hematologic conditions, such as chronic myelomonocytic leukaemia (CMML), by targeting cancerous cells. The drug is administered through injection and requires careful monitoring for side effects, as it can affect blood cell production and immune function. In addition to its use in cancer therapy, it is also being investigated for potential applications in the treatment of solid tumours and other genetic disorders related to abnormal cell growth.

The demand for Azacitidine is predominantly driven by its application as a chemotherapy drug in the treatment of certain types of blood cancers, which promotes its market expansion. Its application as an antineoplastic agent in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) also boosts its demand in the medical and pharmaceutical industries. Its demand as a reference compound in research studies associated with reprogramming cells to treat various diseases in epigenetic therapy further contributes to its market expansion. Its effectiveness in managing blood cancers by modifying the DNA of cancer cells to stop their growth further fuels its demand, especially in oncology treatments.

Its application in the treatment of other hematologic disorders, including chronic myelomonocytic leukaemia (CMML), also supports its position in the market. Industrial Azacitidine procurement is influenced by factors such as the cost and availability of raw materials (such as synthetic intermediates), regulatory compliance, and stringent environmental guidelines. Technological advancements in biopharmaceutical production, supplier reliability, sustainable practices, and efficient distribution channels also play a vital role in shaping global procurement strategies for Azacitidine.

Raw Material for Azacitidine Production

According to the Azacitidine production plant project report, the major raw materials for Azacitidine production includes Azacytosine, 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose, and Sodium Methoxide.

Production Process of Azacitidine

The extensive Azacitidine production cost report consists of the following industrial production process:

1. Production from Azacytosine: The production process of Azacytidine begins with the bis-silylation of azacytosine using HMDS in the presence of ammonium sulfate to produce trimethylsilylated azacytosine. Then, this silylated compound is coupled with 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose in dichloromethane, with TMS-triflate as a catalyst, to form protected 5-azacitidine. The acetyl groups are further removed by treatment with sodium methoxide in methanol to obtain crude azacitidine. Finally, the crude product is purified by crystallisation from a DMSO/methanol mixture, which leads to the formation of pure azacytidine as the desired product.

Azacitidine is a pyrimidine nucleoside analogue of cytidine, and it functions as a DNA methyltransferase inhibitor with antineoplastic activity. It appears as a white to off-white solid powder and has a density of approximately 1.43 g/cm³. The molecular formula of the compound is C8H12N4O5, and its molecular mass is 244.2 g/mol. It is sparingly soluble in water but insoluble in acetone, ethanol, and methyl ethyl ketone. The compound is soluble in dimethylsulfoxide (DMSO), and it decomposes at its melting point, which is 226–232 degree Celsius. It is very unstable in aqueous media, with rapid degradation occurring within hours of dissolution at room temperature. Extended exposure to this substance may cause serious adverse effects such as anaemia, neutropenia, thrombocytopenia, hepatotoxicity, and renal toxicity. The compound is contraindicated in patients with advanced malignant hepatic tumours and can cause severe fetal harm during pregnancy.